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Background/aim: Vascular endothelial growth factor (VEGF) is associated with various ischemic and inflammatory diseases, and
plays an important role in the development of liver fibrosis and hepatocarcinogenesis in nonalcoholic steatohepatitis (NASH). In this
study, the comparative effect of pioglitazone, quercetin, and hydroxy citric acid on VEGF mRNA in experimentally induced NASH was
investigated.
Materials and methods: The experimental protocol consisted of five groups: control, NASH, NASH + pioglitazone, NASH + quercetin,
and NASH + hydroxy citric acid. The VEGF mRNA expression was evaluated by reverse transcription polymerase chain reaction (RTPCR) analysis for all experimental groups, and the levels of VEGF mRNA were quantitatively measured by densitometry.
Results: A higher expression of VEGF mRNA was found in the hepatic cells of rats with experimentally induced NASH compared to
the control group. A very mild increase in VEGF mRNA expression was observed in the rats treated with quercetin. In contrast, a mild
increase in the expression of VEGF mRNA was observed in the rats treated with pioglitazone and hydroxy citric acid.
Conclusion: Quercetin exhibited an effective inhibition of VEGF mRNA expression, while a lower inhibition of the VEGF mRNA level
was observed in the hydroxy citric acid- and the pioglitazone-treated rats.
Key words: Pioglitazone, quercetin, hydroxy citric acid, VEGF mRNA, nonalcoholic fatty liver disease (NAFLD), nonalcoholic
steatohepatitis (NASH)

1. Introduction
Vascular endothelial growth factor (VEGF) is an inducer
of angiogenesis, which is a hallmark of various ischemic
and inflammatory diseases (1). An in vitro study
revealed that leptin exerts proangiogenic activity in the
presence of VEGF. VEGF plays an important role in the
development of liver fibrosis and hepatocarcinogenesis
in nonalcoholic steatohepatitis (NASH) (1,2). NASH is
an asymptomatic disease belonging to the nonalcoholic
fatty liver disease (NAFLD) spectrum, but if it is severe
it often leads to cirrhosis of the liver, which is an endstage liver disease, if not diagnosed and treated properly
*
		
		
**

(3–6). In our previous studies we have reported the effects
of pioglitazone, quercetin, and hydroxy citric acid on
the hepatic biomarkers, lipid profile, and lipoproteins in
experimentally induced NASH (7,8).
We have studied the comparative effects of pioglitazone,
quercetin, and hydroxy citric acid on the status of lipid
peroxidation and antioxidants in experimental NASH (9),
but very little information is known about the role of VEGF
in NASH. The present study explores the comparative
effects of pioglitazone, quercetin, and hydroxy citric acid
on VEGF mRNA in experimentally induced NASH.
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2. Materials and methods
The experimental model of NASH in rats was established
by feeding the animals a high-fat diet for 8 weeks (9,10),
and this model was used to conduct a comparative study
of the roles of pioglitazone, quercetin, and hydroxy citric
acid on various parameters in NASH. Male Wistar rats
weighing approximately 250 g were housed in solidbottomed polypropylene cages under strict veterinary
supervision, and maintained in control rooms with a 12-h
light/12-h dark cycle. The animals received water and
a commercial rat diet, standard diet, or high-fat diet ad
libitum according to the experimental protocol. This study
conformed to the guiding principles of the Institutional
Animal Ethical Committee (IAEC), the Committee for the
Purpose of the Control and Supervision of Experiments
on Animals (CPCSEA), and the Guide for the Care and
Use of Laboratory Animals (IAEC Approval Numbers:
001/006/2010 and 01/007/2011).
The male Wistar rats selected for the study were divided
into eight groups as shown in Table 1 (9–11).

After the experimental period, the animals were
sacrificed, after 12 h of fasting, by cervical decapitation.
Liver tissue samples were collected from the sacrificed
animals and stored until reverse transcription polymerase
chain reaction (RT-PCR) analysis was conducted, using an
Applied Biosystem model PCR machine. The total RNA
was isolated from liver samples using a cooling centrifuge
(Remi model). The total RNA was used as the template to
synthesize complementary DNA (cDNA), with 2.5 units
of Moloney murine leukemia virus reverse transcriptase
in 10 µL of buffer containing 10 mM Tris-HCl, pH 8.3, 50
mmol of KCl, 5 mmol of random hexamer, and 1.4 units of
ribonuclease inhibitor. The RT was performed at 42 °C for
15 min. The resulting cDNA was used as the template for
the subsequent PCR analysis.
The specific primer set for the rat VEGF receptor is
shown in Table 2. The PCR was performed in 50 µL of buffer
containing 10 mmol Tris-HCl, pH 8.3, 2 mmol MgCl2,
50 mmol KCl, 0.2 mmol of each deoxyribonucleoside
triphosphate, 0.4 µmol of each primer, and 2 U of Taq DNA

Table 1. Division of the male Wistar rats into experimental groups in this study.
Sl.No

Name of the group

No. of animals
in group (n)

Description

1

Group 1; Controls

6

The control rats received the regular standard diet for 8 weeks.

2

Group 2; NASH

6

The rats were fed a high-fat diet for 8 weeks to induce NASH.

6

These rats were fed the standard diet for 4 weeks, and were
then fed the standard diet and intragastrically administered
pioglitazone (4 mg/kg. b.wt.; 0.5% methyl cellulose w/v) for
the next 4 weeks.

3

Group 3; Pioglitazone control

4

Group 4; Quercetin control

6

These rats were fed the standard diet for 4 weeks, and were
then fed the standard diet and intragastrically administered
quercetin (20 mg/kg. b.wt.) dissolved in 1% DMSO v/v for the
next 4 weeks.

5

Group 5; Hydroxy citric acid control

6

These rats were fed the standard diet for 4 weeks, and were
then fed the standard diet and intragastrically administered
hydroxy citric acid (150 mg/kg. b.wt.) for the next 4 weeks.

6

These rats were fed a high-fat diet for 4 weeks, and were
then fed the high-fat diet and intragastrically administered
pioglitazone (4 mg/kg. b.wt.; 0.5% methyl cellulose w/v) for
the next 4 weeks.

6

These rats were fed a high-fat diet for 4 weeks, and were
then fed the high-fat diet and intragastrically administered
quercetin (20 mg/kg. b.wt.) dissolved in 1% DMSO v/v for the
next 4 weeks.

6

These rats were fed a high-fat diet for 4 weeks, and were then
fed the high-fat diet and intragastrically administered hydroxy
citric acid (150 mg/kg. b.wt.) for the next 4 weeks.

6

7

8

Group 6; NASH + pioglitazone

Group 7; NASH + quercetin

Group 8; NASH + hydroxy citric acid
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Table 2. Specific primer sets for rat liver VEGF.
S. No

mRNA

Sequence

Product length

2

VEGF

5’-CCTGGTGGACATCTTCCAGGAGTACC-3’ (sense)
5’-GAAGCTCATCTCTCCTATGTGCTGGC-3’ (antisense)

196

polymerase. The reaction conditions for the amplification
of the genes of interest are presented in Table 3. Tenmicroliter aliquots of the PCR products were subjected
to electrophoresis on a 1.25% agarose gel, and the DNA
was visualized by ethidium bromide staining. The location
and sizes of the products were determined using a 100-bp
ladder (Genei Lab, India). The gel was then photographed
using a UV transilluminator (Medox Bio Transilluminator
model). The quantification of VEGF expression was
performed through densitometry, using the Image Master
VDS software.
3. Statistical analysis
All data are presented as means ± standard errors of
the mean (SEM). Statistical analysis among groups was
performed by one-way analysis of variance (ANOVA),
followed by Dunnett’s T3 comparison post-hoc test.
Differences were considered statistically significant if P <
0.05.
4. Results
Histopathological studies revealed the ingestion of the
high-fat diet for 8 weeks produces all the prominent
characteristics of NASH and the principal histological
features of NASH, including steatosis and inflammation,
which mimics the NASH in humans (9). Treatment with
drugs alone does not cause any deleterious effects. There
was inflammation observed, with no fatty degeneration
on treatment with pioglitazone (9), and local hepatocyte
necrosis with inflammatory collections was seen
on treatment with hydroxy citric acid (9). However,
hepatocytes appear normal with no obvious fatty or
inflammatory changes on treatment with quercetin (9).
VEGF mRNA expression was analyzed by the RT-PCR
in all of the experimental groups, as shown in Figure 1.
Lane 1 represents the expression of VEGF mRNA in the
control group (group 1). Lane 2 represents the expression
of VEGF mRNA in the rats with experimentally induced

NASH (group 2). Lane 3 represents the expression of VEGF
mRNA in the rats with experimentally induced NASH
treated with quercetin (group 7, NASH + quercetin). Lane
4 represents the expression of VEGF mRNA in the rats with
experimentally induced NASH treated with pioglitazone
(group 6, NASH + pioglitazone). Lane 5 represents the
expression of VEGF mRNA in the rats with experimentally
induced NASH treated with hydroxy citric acid (group 8,
NASH + HCA). A higher expression of VEGF mRNA was
observed in the hepatic cells of the rats with experimentally
induced NASH (group 2), compared with that observed in
the control group (Lane 2, group 2). The quantification of
VEGF expression was performed through densitometry,
using the ImageMaster VDS software, and the results are
shown in Figure 2.
Compared with the rats with experimentally induced
NASH (Lane 2, group 2), a very mild increase in the
expression of VEGF mRNA was observed in the rats with
experimentally induced NASH treated with quercetin
(Lane 3, group 7, NASH + quercetin), and mild increases
were observed in the rats with experimentally induced
NASH treated with pioglitazone (Lane 4; group 6; NASH +
pioglitazone) and in the rats with experimentally induced
NASH treated with hydroxy citric acid (Lane 5; group 8,
NASH + HCA). The drug quercetin showed an effective
inhibition of VEGF mRNA expression, as evidenced in
Figures 1 and 2 (Lane 3), and a lower inhibition of the
VEGF mRNA level was observed in the hydroxy citric
acid- and the pioglitazone-treated rats (Lanes 4 and 5).
5. Discussion
The RT-PCR analysis of VEGF mRNA was performed in
all of the groups, and the results are presented in Figures 1
and 2. A higher expression of VEGF mRNA was observed
in the hepatic cells of rats with experimentally induced
NASH (group 2), compared with that found in the control
group (Lane 2, group 1). Compared with the rats with
experimentally induced NASH, a mild increase in the

Table 3. Reaction conditions for PCR.
cDNA

Initial denaturation
°C (min)

Denaturation
°C (min)

Annealing
°C (min)

Extension
°C (min)

Final extension
°C (min)

No. of cycles

VEGF

94 (5 min)

94 (1 min)

55 (1 min)

72 (2 min)

72 (3 min)

33
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Figure 1. Analysis of vascular endothelial growth factor (VEGF) messenger RNA (VEGF mRNA) expression by reverse transcription
polymerase chain reaction (RT-PCR). Lane 1 – Control; Lane 2 – NASH; Lane 3 – NASH + quercetin; Lane 4 – NASH + pioglitazone;
Lane 5 – NASH + hydroxy citric acid; Lane M - Marker.

VEGF mRNA expression
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Figure 2. Quantification of VEGF mRNA expression through densitometry using the Image Master VDS software. The values are
expressed as the mean ± standard error of mean (SEM) from six animals in each group; aP < 0.001 compared to the control group; bP <
0.01 compared to the NASH group.

expression of VEGF mRNA was observed in the rats with
experimentally induced NASH treated with pioglitazone
(Lane 4, group 6, NASH + pioglitazone).
Pioglitazone restores the blood flow and capillary
density in ischemic muscle, and this process is associated
with increased expression of VEGF (12). VEGF mRNA
expression in liver tissue was found to be decreased by
pioglitazone treatment, compared with the control group,
and this result is concordant with the findings of a previous
study conducted in muscles. In contrast, a high dose
of pioglitazone suppresses vascular endothelial growth
factor (VEGF)-induced endothelial cell proliferation,
by suppressing VEGF receptor 1 (Flt-1) and 2 (Flk/
KDR) expression in vitro (13). These studies provide
supporting evidence for the present findings, which show
that pioglitazone treatment decreases the levels of growth
factors in liver tissue.
Hydroxy citric acid treatment resulted in a mild
increase in the expression of VEGF mRNA in rats with
experimentally induced NASH (Lane 5, group 8, NASH +
HCA), compared with rats with experimentally induced
NASH (Lane 2, group 2). In contrast, quercetin treatment
resulted in a very mild increase in the expression of VEGF
mRNA in rats with experimentally induced NASH (Lane
3, group 7, NASH + quercetin), compared with rats with
experimentally induced NASH (Lane 2, group 2).

VEGF induction is dependent on quercetin-mediated
hypoxia-inducible factor-1 (HIF-1) activation. Quercetin
delays the appearance of HIF-1α protein by inhibiting
HIF-prolyl hydroxylase (HPH), which is the key enzyme
for HIF-1α hydroxylation and subsequent von Hippel
Lindau-dependent HIF-1α degradation (12). Our data
suggest that the clinical effect of quercetin may be partly
attributed to the activation of the HIF-1-VEGF angiogenic
pathway, through the inhibition of HPH, and that the
chelating moieties of quercetin are required for the
inhibition of HPH.
Quercetin activates the HIF-1-VEGF angiogenic
pathway by inhibiting HIF-prolyl hydroxylase, as
determined through a structural analysis of quercetin.
Quercetin, which is a flavonol found in several varieties
of berries at concentrations of up to 70–80 mg/kg dry wt.,
has been found to inhibit the growth and stimulate the
apoptosis of cancer cells (14).
6. Conclusion
Based on our findings, quercetin exhibits an effective
inhibition of VEGF mRNA expression, and a slight
inhibition of the VEGF mRNA level was observed in
the hydroxy citric acid- and the pioglitazone-treated
rats. This study shows the therapeutic value of quercetin,
pioglitazone, and hydroxy citric acid.
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